Investor Ideas #Potcasts #Podcast #509, #Cannabis News and #Stocks on the Move; (NASDAQ: $VFF) (TSXV: $NUMI.V) (NASDAQ: $APHA) (OTCQB: $PHCG) (NYSE: $XXII)
Delta, Kelowna, BC, December 17, 2020 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2020/121720-StocksToWatch.mp3
Read this in full
at https://www.investorideas.com/news/2020/cannabis-potcasts/12171VFF-NUMI-APHA-PHCG-XXII.asp
Hear the investor ideas potcast on Spotify
Hear Investor ideas cannabis potcast on iTunes
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com
"Potcast" featuring cannabis news, stocks to watch as well as
insights from thought leaders and experts.
In
today’s podcast we will be looking at a few private and public company
announcements.
Village
Farms International, Inc. (NASDAQ:VFF) (TSX:VFF) today
announced further expansion of its Cannabis 2.0 offerings,
including its first cannabis-infused gummy products based on the propriety
technology of White Rabbit OG.
Exclusive Partnership with White
Rabbit OG for Edibles Formulation and Manufacture
Pure Sunfarms has entered into an
exclusive partnership agreement with White Rabbit, a BC-based craft cannabis
food formulation and development company, for the formulation and manufacture
of edible cannabis-infused gummies using White Rabbit's proprietary EAT ME
Technology. EAT ME Technology is a proprietary, all-natural emulsion blend that
ensures cannabis extract is dispersed equally in each gummy and increases the
bioavailability of the THC and CBD molecules, allowing for consistent results
and near-perfect dosing. Edibles from both companies will be distributed and
sold by Pure Sunfarms under their respective brands.
Pure Sunfarms and White Rabbit
cannabis-infused gummies are expected to be the only gummies in Canada that are
made using real pure fruit. In addition, they are plant-based, allergen-free,
non-GMO, vegan and preservative-free.
"We are thrilled to exclusively
partner with White Rabbit OG to develop a unique product made with real fruit.
Pure Sunfarms and White Rabbit both share the fundamental belief in providing
consumers with a pure cannabis experience, which we know consumers
appreciate," said Mandesh Dosanjh, President and Chief Executive Officer,
Pure Sunfarms.
"White Rabbit is a true
Canadian leader in the formulation of edibles. Combined with the absorption
benefits of White Rabbit's EAT ME Technology, we see lots of potential in this
rapidly growing segment of the cannabis market."
"As an innovative craft BC
brand, aligning ourselves with a partner who shares our vision and values, sees
the opportunities for growth and is intuitive about what cannabis consumers are
looking for is important to us," said Kyrsten Dewinetz, Co-Founder and
Chief Executive Officer, White Rabbit. "We are excited to have partnered
with Pure Sunfarms, a well-respected, fast-growing licensed producer, whose
approach and commitment to quality is complementary to our own. Together, we
look forward to setting the new standard of cannabis edibles, and delivering
products that not only taste great, but provide consumers with a high-quality
experience."
"This partnership is yet
another example of our' prudent, capital-efficient approach to pursuing growth
opportunities in cannabis," said Michael DeGiglio, CEO, Village Farms
International. "We expect edibles
to be an increasingly meaningful part of the Canadian cannabis market and
exclusively partnering with a formulation and technology leader allows for the
expedited launch of unique products with minimal capital investment."
Pure Sunfarms plans to launch its
Pure Sunfarms-branded cannabis-infused gummies in early 2021, while White
Rabbit plans to launch its brand to the recreational cannabis retail markets in
British Columbia, Alberta, Saskatchewan, and Ontario, as well as nationally
through Medical Cannabis by Shoppers in the coming weeks. White Rabbit's first
products will consist of Craft Blueberry and Craft Sour Peach flavours, each
offered in packs of four 2.5-mg THC per gummy (total of 10-mg THC per pack),
with new flavours and potencies to be added in 2021.
The Pure Sunfarms/White Rabbit
partnership agreement is initially for a period of two years, with the option
to renew the agreement annually thereafter.
Pure Sunfarms Expands Cannabis 2.0
Offering with Launch of High-THC Vapes and Adds New Strains to its Full
Spectrum Vape Collection
Building on the success of its full
spectrum vape products, which were launched in Ontario, British Columbia and
Alberta, Pure Sunfarms will expand its vape product offering with the
introduction of new high-THC vape products in the coming weeks. Each 510
cartridge will feature 840-mg to 900-mg of concentrated THC, intended for
consumers seeking a high-THC experience.
"Our high-THC vape products
have just one ingredient: pure cannabis extract," said Mr. Dosanjh. "They contain no additives, no
alternative botanical ingredients, no flavouring agents, no thinning agents, no
additional cannabinoids. And like all Pure Sunfarms' products, they offer
consumers quality at an attractive price."
Pure Sunfarms will also add two new
strains, Critical Kali Mist and Headband, to their full spectrum vape portfolio
in the weeks ahead.
Numinus
Wellness Inc. (TSXV:
NUMI), a company creating an ecosystem of solutions centred
on the research, development, and delivery of safe, evidence-based, accessible
psychedelic-assisted psychotherapies, has
completed the first legal extraction of Psilocybe
mushrooms in Canada by a public company for research and
development purposes. This follows Numinus' successful completion of the
cultivation and harvest of the first legal flush of Psilocybe mushrooms at Numinus Bioscience, the Company's 7,000
square foot analytics and research laboratory.
"Completing the first legal
extraction of Psilocybe mushrooms in
Canada is a critical next step to providing a natural product for safe,
evidence-based psilocybin-assisted psychotherapies to those in need," said
Payton Nyquvest, CEO, Founder, and Chairman. "Numinus continues to be a
vanguard of positive change for the industry, and this announcement
demonstrates our ability to deliver yet another first."
Numinus Bioscience is establishing
itself at the forefront of analytical testing for psychedelic substances, as a
centre of excellence for psychedelic product research and development, and as
an ancillary for psychedelic therapy clinical trials. Health Canada licences,
scientific expertise, and state-of-the-art technologies facilitate ongoing
innovation, while revenue from high-throughput contract cannabis testing is
reinvested to further its psychedelic initiatives.
"This is an important milestone
in our comprehensive research strategy, following our successful harvest
announced in October," said Sharan Sidhu, Science Officer and General
Manager. "In the extraction process, Numinus Bioscience's goal is to
optimize Psilocybe mushrooms to
standardize psilocybin and multiple therapeutically important components,
increasing the efficacy of the extract. To further our position as a centre of
excellence in the space, we are in the process of submitting amendments to
supply the extract for use in clinical trials and the Special Access Programme,
which, when accepted, will mark a significant move forward in scaling the
delivery of psychedelic-assisted therapies."
"While direct comparisons
cannot be made, there is a clear recognition in the cannabis space that
synthetic cannabinoids are far less attractive than naturally occurring
cannabinoids," indicated Dr. Evan Wood, Numinus' Chief Medical Officer. "Numinus
is of the view that, ultimately, nature knows best, and we're excited to be at
the forefront of exploring the fascinating world of working with Psilocybe mushrooms as part of a focused
drug development program."
This announcement follows Numinus'
advocacy work that contributed to Health Canada's groundbreaking announcement
of its intention to revise the Special Access Programme (SAP) to permit access
to MDMA and psilocybin-assisted psychotherapy in the same way other
investigational medications are accessed in Canada. In addition, earlier this
week Numimius announced the exciting acquisition of Montreal -based Mindspace
Psychology Services Inc (DBA Mindspace Wellbeing) bringing together the
capabilities of two leading Canadian organizations to develop and scale delivery
of evidence-based psychedelic-assisted psychotherapy.
Health Canada's Notice of Intent
regarding the SAP will be open for public consultation and comments for the
next 60 days, and Numinus strongly encourages the community to weigh in on the
benefits of the revision. View the notice here: http://www.gazette.gc.ca/rp-pr/p1/2020/2020-12-12/html/notice-avis-eng.html#nb2.
To share comments and thoughts
related to the SAP, please email hc.csd.regulatory.policy-politique.reglementaire.dsc.sc@canada.ca.
Aphria
Inc. (TSX:
APHA) (NASDAQ:
APHA), a leading global cannabis company
inspiring and empowering the worldwide community to live their best life,
today announced the launch of Broken Coast Cannabis Inc.'s newest innovation and proprietary
strain, Pipe Dream.
With its unique and distinctive
characteristics, which include a bold bud structure, strong smell and look, and
a spicy-gas profile with high THC (18-24%) content, 'Pipe Dream' was ultimately
selected as the newest Broken Coast flower strain after 15-months of careful
testing at its British Columbia-based cultivation facility.
"There aren't many cannabis
plants that are genetically different to what's out there," said Kevin
Anderson, Broken Coast's Head Grower. "To find a plant that scores so high
in all regards of our testing is really one in several hundred - it's very
rare. Pipe Dream is the one in several hundred and we think Canadians will
really love the spicy and gassy profile, as it's truly different to anything
else in our current strain offering but still the high-quality product
consumers have come to expect from Broken Coast."
To unearth a cultivar worthy of the
Broken Coast brand required the master grow team to plant, nurture and evaluate
thousands of seedlings, seeking to identify and accentuate the traits that
produce a truly exceptional smoke. Some felt a flower this special was nothing
but a Pipe Dream. Now Canadians can decide for themselves.
Pipe
Dream has
a very dense and round bud structure thickly covered with bright trichomes. The
lime green and purple flower also has a touch of fruitiness within its spicy
and pungent profile. Pipe Dream is
available in BC in 3.5g whole flower online and in retail and will be rolling
out to the rest of the country (except for Quebec) over the next few months. In
addition, 5g and 10g formats are also available to medical clients.
This is the second innovation
recently launched by Broken Coast, following the recently announced expansion
of its product portfolio and entry into the 2.0 market with the launch of 510
vapes.
Pure
Harvest Corporate Group, Inc. (OTCQB:
PHCG), a publicly-traded holding company focused on
emerging and high-growth industries, announced the
development of a cannabinoid compound which the Company believes has numerous
applications as a versatile product ingredient. The working name for the
cannabinoid compound is “Complex 612.”
“Complex 612 is a patent pending
formulation created through extracting and compressing specific compounds
within the hemp plant. Together with the addition of an antioxidant synergist
to augment bioavailability and predictably of the experience in the ‘vehicle’
it is utilized within traditional, functional foods, confections, and
beverages. Complex 612 also serves as a catalyst when paired with a variety of
active compounds from plants including mushrooms, adaptogens, nootropics and
others,” said Dr. James Rouse, NMD, Test Kitchen Chief Formulator. “The possibilities
are limitless.”
“We believe Complex 612 and the wide
variety of products and product enhancements that will come from it will be a
game changer for the Company and this industry,” stated Matthew Gregarek, CEO,
Pure Harvest Corporate Group. “We are already far down the road in our product
development and planned roll-out and we are extremely excited to bring this
product to market.
“Renowned cannabis attorney Donnie
Emmi will officiate the product development and launch as CEO of our wholly owned
subsidiary Test Kitchen and world-class marketing consultants Shipyard are
handling everything from branding to our go-to-market strategy.
“I believe that I have truly
assembled an All-Star team worthy of this tremendous innovation and am so
immensely proud of what we’ve done and excited about what the very near future
holds for Pure Harvest and its shareholders,” added Gregarek.
22nd
Century Group, Inc. (NYSE:
XXII), a leading plant-based, biotechnology company focused
on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis
research, announced
today that it was granted a new U.S. patent related to the
control of cannabinoid and terpene production in plants. This new intellectual
property exclusively provides 22nd Century with unique and powerful tools to
alter the cannabinoid biosynthesis pathway in hemp/cannabis plants.
"We are delighted to receive
this patent, which is the result of work carried out by our own scientists.
This important, new technology will allow us to genetically modify
hemp/cannabis plants to modulate their cannabinoid and terpene profiles in
order to tailor these plants’ therapeutic qualities and enhance the consumer’s
hemp/cannabis experience," said Juan Sanchez Tamburrino, Ph.D., vice
president of research & development at 22nd Century Group. "Our patent
application describes eight promoters, which are essentially molecular on/off
switches, covering all of the major steps in the cannabinoid biosynthesis
pathway. Typically, developing hemp/cannabis plants with new cannabinoid or
terpene profiles could take 10 to 20 years using traditional breeding methods.
Now, with the combined technologies and know-how of 22nd Century and KeyGene,
we expect to shorten the development timeline to create new, differentiated,
hemp/cannabis plant lines in just 4 to 5 years. Doing so will provide the
Company and its potential licensees and customers with significant competitive advantage
as hemp/cannabis continues to penetrate the life science, consumer product, and
pharmaceutical markets.”
“At 22nd Century Group, we take a
scientific and solutions-oriented approach to advancing ground-breaking,
plant-based technology. We are excited to secure this patent, and we believe
that it demonstrates our unique and leading role in plant science innovation
within the $100 billion global hemp/cannabis market,” said James A. Mish, chief
executive officer of 22nd Century Group.
The new patent, published as U.S.
Patent No. 10,787,674 B2 and entitled "Trichome specific promoters for the
manipulation of cannabinoids and other compounds in glandular trichomes,"
enables 22nd Century to develop and deliver new hemp/cannabis plants that are
designed to produce cannabinoids more efficiently. The Company can potentially
increase the yield of plants, stabilize the level of cannabinoids that are
produced, and create custom cannabinoid profiles optimized for specific
therapeutic uses. 22nd Century will also be able to potentially modulate the
terpene levels within the plant – increasing them to deliver new strains of
cannabis for the adult-use/recreational market and reducing them to remove the
odor and taste for improved application in foods and beverages.
Cannabinoids, such as CBD, CBC, and
CBG, are valuable compounds that hold great promise for the development of new
medicines and other therapeutic applications. Cannabis sativa is the only plant species that produces significant
amounts of these compounds including more than one hundred different
cannabinoids in varying quantities. In nature, cannabis plants restrict
production of these potentially toxic compounds to the trichomes which are tiny
hair-like stems and globes that grow on the surface of the plant. To
successfully manipulate cannabinoids, the Company’s new technology activates
molecular promoters, “on/off switches,” specifically
and only in the plant’s trichomes where the majority of cannabinoids are
produced. These regulatory sequences dynamically enhance or restrict gene
expression levels, controlling the expression of genetic information that leads
to the production of cannabinoids.
Investor ideas reminds all
listeners to read our disclaimers and disclosures on the Investorideas.com
website and that this podcast is not an endorsement to buy products or services
or securities. Investors are reminded all investment involves risk and possible
loss of investment.
Investors can trade these stocks and other ideas on our site using
our list of top
stock trading apps including Robinhood, Acorn, Stash and
others.
Learn more about
our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
To hear more
Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Investorideas.com
podcasts are also available on iTunes,
Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified
word mark Trademark on the blockchain through Cognate, Inc. CM
Certification-Registration Number: 10468217708
About Investorideas.com - News that
Inspires Big Investing Ideas
Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts and
videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water,
renewable energy and more. Investor Idea’s original branded content includes
the following podcasts and columns : Crypto Corner , Play
by Play sports and stock news column, Investor Ideas
Potcasts Cannabis News and Stocks on the Move podcast and
column, Cleantech
and Climate Change , Exploring
Mining the AI
Eye .
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other
news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations
of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow
us on Facebook https://www.facebook.com/Investorideas
Follow
us on YouTube https://www.youtube.com/c/Investorideas
Download
our Mobile App for
iPhone and Android
Join
our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800
665 0411
Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory
No comments:
Post a Comment